Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Atorvastatin + colchicine** is a combination of two small-molecule drugs: atorvastatin, a statin used primarily for lipid lowering and cardiovascular risk reduction, and colchicine, an anti-inflammatory agent mainly used to treat gout and pericarditis. Atorvastatin works via competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, resulting in decreased cholesterol production and reduced risk of atherosclerotic events. Colchicine acts primarily by binding to tubulin, inhibiting microtubule polymerization and thus modulating leukocyte activity and inflammatory responses. This combination is of particular clinical interest in patients with both cardiovascular disease and indications for colchicine (e.g., gout, pericarditis) or following recent evidence for colchicine in atherosclerotic risk reduction. However, both drugs are metabolized by CYP3A4 and are substrates for P-glycoprotein, leading to significant drug-drug interaction risk, notably increased likelihood of myopathy and rhabdomyolysis due to elevated plasma levels when administered together[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + colchicine.